Loading company…
Morphocell Technologies develops engineered tissue therapies for liver diseases, including its ReLiver® program.
Founded in 2018 and based in Laval, Canada, Morphocell Technologies develops tissue engineering treatments for liver diseases. Its ReLiver® program is designed to address severe liver conditions in adults and children. The company collaborates with research organizations including CQDM and the Stem Cell Network. In December 2025, it raised USD 10.00 mn in Series A funding led by Investment Quebec, with CDP Venture Capital participating, to advance clinical development and manufacturing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in